계명대학교 의학도서관 Repository

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Metadata Downloads
Author(s)
Kim H.Kim J.Byeon S.Jang K.-T.Hong J.Y.Lee J.Park S.H.Park J.O.Park Y.S.Lim H.Y.Kang W.K.Kim S.T.
Keimyung Author(s)
Kim, Hye Ra
Department
Dept. of Internal Medicine (내과학)
Journal Title
Oncology
Issued Date
2021
Volume
99
Issue
6
Keyword
Biliary tract cancerProgrammed death ligand 1 expressionPrognosis
Abstract
Background:
Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhibitors in various tumors. However, there are limited data reporting on the role of PD-L1 in advanced BTC patients.

Patients and Methods:
We analyzed 186 patients with advanced BTC who received palliative gemcitabine and platinum between May 2010 and December 2019. All patients were evaluated for PD-L1 expression by combined positive score positivity.

Results:
Of the 186 patients, the primary tumor location was intrahepatic cholangiocarcinoma (IHCC) in 72 (38.7%), extrahepatic cholangiocarcinoma (EHCC) in 90 (48.4%), and gallbladder (GB) cancer in 24 (12.9%). Among all the patients, 53 (28.5%) had PD-L1 positivity. The median overall survival (OS) of patients with PD-L1 positivity or negativity was 12.1 and 15.4 months, respectively. The median progression-free survival (PFS) in patients with PD-L1 positivity or negativity was 5.7 and 7.1 months, respectively. OS and PFS were not statistically different between groups. In subgroup analysis, EHCC patients with PD-L1 negativity had more favorable OS (17.2 vs. 11.6 months, p = 0.002) and PFS (7.8 vs. 5.4 months, p = 0.005) than those who were PD-L1-positive. However, this finding was not reproduced in patients with IHCC or GB cancer.

Conclusion:
This study demonstrated that PD-L1 expression might be a novel prognostic biomarker in patients with EHCC but not in patients with IHCC or GB cancer.
Keimyung Author(s)(Kor)
김혜라
Publisher
School of Medicine (의과대학)
Citation
Kim H. et al. (2021). Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Oncology, 99(6), 365–372. doi: 10.1159/000514404
Type
Article
ISSN
1423-0232
Source
https://www.karger.com/Article/Abstract/514404
DOI
10.1159/000514404
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43646
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.